1-4 of 4
Gregory P. Adams
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Human Leukocyte Antigen–Presented Macrophage Migration Inhibitory Factor Is a Surface Biomarker and Potential Therapeutic Target for Ovarian Cancer

Andrea M. Patterson, Saghar Kaabinejadian, Curtis P. McMurtrey, Wilfried Bardet, Ken W. Jackson, Rosemary E. Zuna, Sanam Husain, Gregory P. Adams, Glen MacDonald, Rachelle L. Dillon, Harold Ames, Rico Buchli, Oriana E. Hawkins, Jon A. Weidanz, William H. Hildebrand
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (2): 313–322.
https://doi.org/10.1158/1535-7163.MCT-15-0658
Published: 07 February 2016
View article titled, Human Leukocyte Antigen–Presented Macrophage Migration Inhibitory Factor Is a Surface Biomarker and Potential Therapeutic Target for Ovarian Cancer
Open the PDF for Human Leukocyte Antigen–Presented Macrophage Migration Inhibitory Factor Is a Surface Biomarker and Potential Therapeutic Target for Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Impact of Intrinsic Affinity on Functional Binding and Biological Activity of EGFR Antibodies

Yu Zhou, Anne-Laure Goenaga, Brian D. Harms, Hao Zou, Jianlong Lou, Fraser Conrad, Gregory P. Adams, Birgit Schoeberl, Ulrik B. Nielsen, James D. Marks
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (7): 1467–1476.
https://doi.org/10.1158/1535-7163.MCT-11-1038
Published: 05 July 2012
View article titled, Impact of Intrinsic Affinity on Functional Binding and Biological Activity of EGFR Antibodies
Open the PDF for Impact of Intrinsic Affinity on Functional Binding and Biological Activity of EGFR Antibodies in another window
Includes: Supplementary data
Journal Articles

Single-Chain Antibody-Based Immunotoxins Targeting Her2/neu: Design Optimization and Impact of Affinity on Antitumor Efficacy and Off-Target Toxicity

Yu Cao, James D. Marks, Qian Huang, Stephen I. Rudnick, Chiyi Xiong, Walter N. Hittelman, Xiaoxia Wen, John W. Marks, Lawrence H. Cheung, Kim Boland, Chun Li, Gregory P. Adams, Michael G. Rosenblum
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (1): 143–153.
https://doi.org/10.1158/1535-7163.MCT-11-0519
Published: 09 January 2012
View article titled, Single-Chain Antibody-Based Immunotoxins Targeting Her2/neu: Design Optimization and Impact of Affinity on Antitumor Efficacy and Off-Target Toxicity
Open the PDF for Single-Chain Antibody-Based Immunotoxins Targeting Her2/neu: Design Optimization and Impact of Affinity on Antitumor Efficacy and Off-Target Toxicity in another window
Includes: Supplementary data
Journal Articles

Development of engineered antibodies specific for the Müllerian inhibiting substance type II receptor: a promising candidate for targeted therapy of ovarian cancer

Qing-an Yuan, Heidi H. Simmons, Matthew K. Robinson, Maria Russeva, Wayne A. Marasco, Gregory P. Adams
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2006) 5 (8): 2096–2105.
https://doi.org/10.1158/1535-7163.MCT-06-0115
Published: 23 August 2006
View article titled, Development of engineered antibodies specific for the Müllerian inhibiting substance type II receptor: a promising candidate for targeted therapy of ovarian cancer
Open the PDF for Development of engineered antibodies specific for the Müllerian inhibiting substance type II receptor: a promising candidate for targeted therapy of ovarian cancer in another window